SCS
ITCI

Syquant Capital SAS’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Syquant Capital SAS’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-266,228
Closed -$35.1M – 24
2025
Q1 		$35.1M Buy
+266,228
New +$33.2M 24.92% 2

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Syquant Capital SAS's ITCI Position: Q2 2025 in Review

Syquant Capital SAS sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 266,228 shares — an estimated $35.1M sold.

Syquant Capital SAS first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $35.1M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Syquant Capital SAS reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Syquant Capital SAS sold 266,228 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $35.1M.
  • Syquant Capital SAS first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Syquant Capital SAS's Intra-Cellular Therapies Inc. position peaked at $35.1M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Syquant Capital SAS's 13F filing for Q2 2025, filed 15 Jul 2025.